https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-12-07 / Sci Transl Med 2016 12;8(368):368ra171
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-12-07 / Sci Transl Med 2016 12;8(368):368ra1712016-12-07 00:00:002019-02-15 08:32:47Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-12-01 / Urol Oncol 2016 12;34(12):538-547
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-12-01 / Urol Oncol 2016 12;34(12):538-5472016-12-01 00:00:002016-12-01 00:00:00Emerging role of immunotherapy in urothelial carcinoma-Advanced disease
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-11-29 / Melanoma Manag 2016 Dec;3(4):273-289
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-11-29 / Melanoma Manag 2016 Dec;3(4):273-2892016-11-29 00:00:002016-11-29 00:00:00Dendritic cell vaccines for melanoma: past, present and future
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-11-23 / Exp. Hematol. 2017 Feb;46:48-55
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-11-23 / Exp. Hematol. 2017 Feb;46:48-552016-11-23 00:00:002019-02-15 08:51:22Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-11-14 / Bone Marrow Transplant. 2017 Feb;52(2):228-237
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-11-14 / Bone Marrow Transplant. 2017 Feb;52(2):228-2372016-11-14 00:00:002019-02-15 08:51:19Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-11-01 / Immunotherapy 2016 11;8(11):1293-1308
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-11-01 / Immunotherapy 2016 11;8(11):1293-13082016-11-01 00:00:002019-02-15 08:47:27Novel vaccines for glioblastoma: clinical update and perspective
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-10-25 / Trends Immunol. 2016 12;37(12):855-865
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-10-25 / Trends Immunol. 2016 12;37(12):855-8652016-10-25 00:00:002019-02-15 08:45:15Dendritic Cells and Cancer Immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-10-18 / Oncoimmunology 2016;5(11):e1232237
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-10-18 / Oncoimmunology 2016;5(11):e12322372016-10-18 00:00:002019-02-15 08:49:47Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-10-17 / Therap Adv Gastroenterol 2017 Jan;10(1):168-194
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-10-17 / Therap Adv Gastroenterol 2017 Jan;10(1):168-1942016-10-17 00:00:002016-10-17 00:00:00Immunotherapy in pancreatic cancer treatment: a new frontier
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-09-29 / Cancer Immunol. Immunother. 2016 12;65(12):1499-1509
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-09-29 / Cancer Immunol. Immunother. 2016 12;65(12):1499-15092016-09-29 00:00:002019-02-15 08:47:26Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma
